This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Björnström, L. Articles by Sjöberg, M. Search for Related Content PubMed PubMed Citation Articles by Björnström, L. Articles by Sjöberg, M.

Mechanisms of Estrogen Receptor Signaling: Convergence of Genomic and Nongenomic Actions on Target Genes

Department of Cell and Molecular Biology, Karolinska Institutet, SE-171 77 Stockholm, Sweden

Address all correspondence and requests for reprints to: Maria Sjöberg, Department of Cell and Molecular Biology, Karolinska Institutet, SE-171 77 Stockholm, Sweden. E-mail: maria.sjoberg{at}cmb.ki.se.

	ABSTRACT

TOP ABSTRACT INTRODUCTION ERE-INDEPENDENT GENOMIC ACTIONS NONGENOMIC ACTIONS OF ESTROGENS NONGENOMIC-TO-GENOMIC SIGNALING:... CONVERGENCE OF GENOMIC AND... RESPONSES TO SYNTHETIC LIGANDS CONCLUDING REMARKS REFERENCES

 
Estrogen receptors (ERs) act by regulating transcriptional processes. The classical mechanism of ER action involves estrogen binding to receptors in the nucleus, after which the receptors dimerize and bind to specific response elements known as estrogen response elements (EREs) located in the promoters of target genes. However, ERs can also regulate gene expression without directly binding to DNA. This occurs through protein-protein interactions with other DNA-binding transcription factors in the nucleus. In addition, membrane-associated ERs mediate nongenomic actions of estrogens, which can lead both to altered functions of proteins in the cytoplasm and to regulation of gene expression. The latter two mechanisms of ER action enable a broader range of genes to be regulated than the range that can be regulated by the classical mechanism of ER action alone. This review surveys our knowledge about the molecular mechanism by which ERs regulate the expression of genes that do not contain EREs, and it gives examples of the ways in which the genomic and nongenomic actions of ERs on target genes converge. Genomic and nongenomic actions of ERs that do not depend on EREs influence the physiology of many target tissues, and thus, increasing our understanding of the molecular mechanisms behind these actions is highly relevant for the development of novel drugs that target specific receptor actions.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION ERE-INDEPENDENT GENOMIC ACTIONS NONGENOMIC ACTIONS OF ESTROGENS NONGENOMIC-TO-GENOMIC SIGNALING:... CONVERGENCE OF GENOMIC AND... RESPONSES TO SYNTHETIC LIGANDS CONCLUDING REMARKS REFERENCES

 
ESTROGENS ARE STEROID hormones that regulate growth, differentiation, and function in a broad range of target tissues in the human body. The most potent and dominant estrogen in humans is 17ß-estradiol, but lower levels of the estrogens estrone and estriol are also present. The biological effects of estrogens are mediated through estrogen receptor (ER) and ß, which are members of a large superfamily of nuclear receptors. These receptors act as ligand-activated transcription factors. The classical mechanism of ER action involves estrogen binding to receptors in the nucleus, after which the receptors dimerize and bind to specific response elements known as estrogen response elements (EREs) located in the promoters of target genes (1). Hormone binding also induces a conformational change within the ligand binding domain of the receptors, and this conformational change allows coactivator proteins to be recruited (2). However, evidence for signaling pathways that deviate from this classical model has emerged, and it is now accepted that ERs can regulate gene expression by a number of distinct mechanisms.

Around one third of the genes in humans that are regulated by ERs do not contain ERE-like sequences (3). The molecular mechanisms by which ERs regulate transcription at alternative response elements are not fully understood but are becoming increasingly clear. ERs can regulate gene expression without binding directly to DNA by modulating the function of other classes of transcription factors through protein-protein interactions in the nucleus (4). The interaction of ERs with the activator protein 1 (AP-1) transcription factor complex is a typical example of such ERE-independent genomic actions. In addition, a number of estrogen-responsive genes that lack EREs contain ERE half-sites, or binding sites for the orphan nuclear hormone receptor SF-1 [SF-1 response elements (SFREs)] that serve as direct ER binding sites (3). ER, but not ERß, is able to bind to SFREs (5).

Estrogens exert some of their effects through the action of ERs on gene expression, but a number of other effects of estrogens are so rapid that they cannot depend on the activation of RNA and protein synthesis. These actions are known as nongenomic actions and are believed to be mediated through membrane-associated ERs. The actions are frequently associated with the activation of various protein-kinase cascades (6). However, nongenomic actions of estrogens may indirectly influence gene expression, through the activation of signal transduction pathways that eventually act on target transcription factors. The functions of many transcription factors, including AP-1, are regulated through protein kinase-mediated phosphorylation, and these transcription factors may thus be targets of nongenomic actions of estrogens. This signaling pathway can be referred to as nongenomic-to-genomic signaling, and it provides for a mechanism, distinct from protein-protein interactions in the nucleus, by which ERs can modulate the functions of transcription factors, and thus regulate the expression of genes that do not contain EREs.

This review surveys our knowledge about the molecular mechanisms by which ERs regulate transcription at alternative response elements. We give examples that show that genomic and nongenomic actions of ERs on target genes converge, and we briefly discuss the responses of ERs to synthetic ligands as a possibility of designing drugs that target specific receptor actions.

	ERE-INDEPENDENT GENOMIC ACTIONS

TOP ABSTRACT INTRODUCTION ERE-INDEPENDENT GENOMIC ACTIONS NONGENOMIC ACTIONS OF ESTROGENS NONGENOMIC-TO-GENOMIC SIGNALING:... CONVERGENCE OF GENOMIC AND... RESPONSES TO SYNTHETIC LIGANDS CONCLUDING REMARKS REFERENCES

 
A number of studies have shown that ERs can regulate transcription without binding directly to DNA. The receptors in such cases are tethered through protein-protein interactions to a transcription factor complex that contacts the DNA, as illustrated in Fig. 1. ERs regulate by this mechanism the expression of a large number of estrogen-responsive genes that do not contain EREs. The mechanism is commonly used by members of the nuclear receptor superfamily and is often referred to as transcriptional cross talk (4).

View larger version (53K): [in this window] [in a new window]   Fig. 1. Schematic Illustration of ER Signaling Mechanisms 1. Classical mechanism of ER action. Nuclear E2-ERs bind directly to EREs in target gene promoters. 2. ERE-independent genomic actions. Nuclear E2-ER complexes are tethered through protein-protein interactions to a transcription factor complex (TF) that contacts the target gene promoter. 3. Ligand-independent genomic actions. Growth factors (GF) activate protein-kinase cascades, leading to phosphorylation (P) and activation of nuclear ERs at EREs. 4. Nongenomic actions. Membrane E2-ER complexes activate protein-kinase cascades, leading to altered functions of proteins in the cytoplasm, e.g. activation of eNOS, or to regulation of gene expression through phosphorylation (P) and activation of a TF.

Genes that contain GC-rich promoter sequences are regulated in a similar manner through the interaction of ERs with the Sp1 transcription factor (19). Increasing numbers of genes are being found that are activated by 17ß-estradiol through ER-Sp1 complexes, including the LDL-R [low-density lipoprotein (LDL) receptor] (20), c-fos (21) and cyclin D1 (22) genes. The actions of ERs at Sp1 binding sites depend on the ligand, the cell type, and the receptor subtype (23), as is the case at for the actions of ERs at AP-1 binding sites (16).

Repression of the IL-6 gene by 17ß-estradiol is mediated through the interaction of ERs with two transcription factors, nuclear factor ß (NF-B) and CCAAT/enhancer binding protein ß (C/EBPß) (24, 25). In addition, it has been suggested that the repression of erythropoiesis by 17ß-estradiol involves the interaction of ERs with the GATA-1 transcription factor (26).

ERs also regulate genes, such as the ß-casein gene, that contain signal transducer and activator of transcription (STAT) 5 binding sites, but the outcome of the interaction of ERs with the STAT5 transcription factor is controversial. Some authors have suggested that STAT5-dependent transcription is repressed by ERs activated by 17ß-estradiol, and that this repression requires an intact ER AF-2 domain (27, 28). Other authors have suggested that the transcriptional activity of STAT5 is increased by ERs in a way that does not depend on the ER AF-2 domain (29).

ERE-independent genomic actions that involve tethering of ERs to other DNA binding transcription factors do not require an interaction between the receptor and DNA, as is the case in the classical mechanism of ER action. However, the DNA binding domain (DBD) of the receptors is frequently involved, although intact DNA binding activity per se is not required (7, 8, 9, 10, 13, 15, 25, 28, 29). Mutational analysis has revealed specific residues within the second zinc finger structure of the ERß DBD that discriminate between the classical mechanism of ER action and the modulation of AP-1 and STAT5 activities through tethering (14). This region is well conserved among nuclear receptors, and GR-mediated repression of AP-1 activity depends on residues within the second zinc finger structure of the GR DBD (30). The DBD may be required for proper protein-protein interactions or it may be involved in recruiting additional coregulator proteins to the promoter region.

	NONGENOMIC ACTIONS OF ESTROGENS

TOP ABSTRACT INTRODUCTION ERE-INDEPENDENT GENOMIC ACTIONS NONGENOMIC ACTIONS OF ESTROGENS NONGENOMIC-TO-GENOMIC SIGNALING:... CONVERGENCE OF GENOMIC AND... RESPONSES TO SYNTHETIC LIGANDS CONCLUDING REMARKS REFERENCES

 
Evidence is accumulating that estrogens exert nongenomic actions—actions that are too rapid to be accounted for by the activation of RNA and protein synthesis. Nongenomic actions are a common property of steroid hormones and are frequently associated with the activation of various protein-kinase cascades (6).

The nongenomic actions of 17ß-estradiol that have been reported include the mobilization of intracellular calcium (31), and the stimulation of adenylate cyclase activity and cAMP production (32, 33). Activation of the MAPK signaling pathway by 17ß-estradiol has been extensively studied in several cell types, including breast cancer (34), endothelial (35), bone (36, 37), and neuroblastoma (38) cells. 17ß-Estradiol also activates the phosphoinositol (PI) 3-kinase signaling pathway in endothelial (35), breast cancer (39), and liver (40) cells.

Some authors have suggested that the nongenomic actions of estrogens are mediated through a subpopulation of the classical ERs, ER and ERß, that is located at the plasma membrane (33, 41). Other authors disagree (42). In endothelial cells, as in other cell types, ERs have been found in caveolae where they activate endothelial nitric oxide synthase (eNOS) through protein kinase-mediated phosphorylation (43, 44, 45). Caveolae are specialized membrane invaginations enriched in the scaffold protein caveolin-1. Caveolae facilitate signal transduction by providing a location for various signaling molecules (46). The only membrane receptors for estrogens that have been found are the classical ERs, ER and ERß. However, an isoform of ER that is alternatively spliced (of molecular mass 46 kDa) and that has a truncated N-terminal domain has been identified in endothelial cells (47). ERs do not contain a trans-membrane domain, and the ability of ER to associate with the plasma membrane may be due to palmitoylation of the receptor (47, 48). The plasma membrane ERs exist as functional dimers when activated by estrogens (49).

It appears that the ligand binding domain of the classical ER, when targeted to the plasma membrane, is sufficient for mediating nongenomic actions of estrogens (50). However, other functional domains of the receptors might contribute to the magnitude of these actions by participating in various protein-protein interactions. It is likely that the interaction of ERs with various scaffold or signaling molecules facilitates the activity. ERs at the plasma membrane associate with the scaffold protein caveolin-1 (44, 51), and with a variety of proximal signaling molecules such as G proteins (33, 52), Src kinase, and ras (34, 53), the p85 regulatory subunit of PI3-kinase (54) and Shc (55). Furthermore, the scaffold protein MNAR promotes the interaction of ER activated by 17ß-estradiol with Src kinase, leading to an increase in Src kinase activity, and hence activation of the MAPK signaling pathway (56).

Membrane ERs also activate membrane tyrosine kinase receptors in various cell types, including breast cancer cells. ER activated by 17ß-estradiol interacts directly with the IGF-I receptor, leading to activation of the IGF-I receptor, and hence activation of the MAPK signaling pathway (57). ER also interacts directly with ErbB2 (HER-2/neu) (58). In addition, ER activated by 17ß-estradiol activates the epidermal growth factor (EGF) receptor by a mechanism that involves activation of G proteins, Src kinase, and matrix metalloproteinases, leading to an increase in MAPK and Akt (protein kinase B) activities (59).

The studies described above suggest that the molecular mechanisms underlying the nongenomic actions of estrogens are specific for the cell type. The responses to estrogens may depend on a number of conditions, such as the set of signal transduction molecules and downstream targets present in the target cell, and thus, the responses are likely to be diverse.

	NONGENOMIC-TO-GENOMIC SIGNALING: A NOVEL MODE OF REGULATING TRANSCRIPTION

TOP ABSTRACT INTRODUCTION ERE-INDEPENDENT GENOMIC ACTIONS NONGENOMIC ACTIONS OF ESTROGENS NONGENOMIC-TO-GENOMIC SIGNALING:... CONVERGENCE OF GENOMIC AND... RESPONSES TO SYNTHETIC LIGANDS CONCLUDING REMARKS REFERENCES

 
Signal transduction pathways may connect the nongenomic actions of estrogens to genomic responses. The functions of many transcription factors are regulated through protein kinase-mediated phosphorylation, and these transcription factors may thus be targets for nongenomic actions of estrogens, as illustrated in Fig. 1. This type of nongenomic-to-genomic signaling is a distinct mechanism by which ERs can regulate transcription at alternative response elements. This mechanism functions in addition to the ERE-independent genomic actions described above that involve protein-protein interactions in the nucleus.

The transcription factors Elk-1 (60), C/EBPß (61), and CREB [cAMP response element (CRE) binding protein] (62) are all targets for phosphorylation by the MAPK signaling pathway. Two processes have been demonstrated in several cell types. These processes are the phosphorylation of Elk-1 that is induced by 17ß-estradiol, and the activation of serum response elements (SREs) by a mechanism that is dependent on ERs and that requires intact MAPK activity (55, 63, 64, 65). C/EBPß and CREB are phosphorylated after the MAPK signaling pathway has been activated by 17ß-estradiol (65), and the phosphorylation of CREB leads to the expression of genes that contain CREs (65, 66, 67). CREB is a target for phosphorylation by the cAMP/protein kinase A signaling pathway (68), in addition to its MAPK-mediated activation. Thus, CREB may also be activated by 17ß-estradiol through the stimulation of cAMP production.

The transcriptional activity of the AP-1 transcription factor complex is regulated through MAPK-mediated phosphorylation (69). Activation of the MAPK signaling pathway by 17ß-estradiol results in enhanced AP-1 DNA binding activity and transcriptional activation (40, 67, 70). In contrast, inhibition of the c-jun amino-terminal kinase signaling pathway by 17ß-estradiol results in repression of AP-1 activity (65). The latter observation agrees with previous results showing that the c-jun amino-terminal kinase signaling pathway, and hence AP-1 phosphorylation and transcriptional activation, are inhibited by other ligand-activated nuclear receptors (71, 72).

The NF-B transcription factor complex is a target for phosphorylation by the Akt kinase (protein kinase B) (73, 74), and activation of the PI3-kinase/Akt signaling pathway by 17ß-estradiol leads to the expression of genes that contain NF-B binding sites (75).

Tyrosine phosphorylation of the STAT family of transcription factors is required for their nuclear translocation and DNA binding activity (76). It has been suggested that additional serine phosphorylation modulates the maximal transcriptional activity of STATs (77). It has been reported that the phosphorylation of endogenous STAT3 and STAT5 on tyrosine and serine residues is induced by 17ß-estradiol in endothelial cells, and that STAT-dependent transcription, by a mechanism that is dependent on ERs and that requires intact MAPK, PI3-kinase, and Src kinase activities, is activated by 17ß-estradiol (78). These observations disagree with a previous study showing that the tyrosine phosphorylation and DNA binding activity of overexpressed STAT5 is decreased by ERs in COS-1 cells, both in the presence and in the absence of 17ß-estradiol (79). The discrepancies between these studies may be explained by differences in experimental conditions, such as the use of different types of cells and the analysis of endogenous or overexpressed proteins.

It is important to note that ER and ERß are also targets of phosphorylation by the MAPK signaling pathway (80, 81). Thus, nongenomic actions of estrogens may modulate the functions of ERs themselves, and in this way augment the classical mechanism of ER action. In addition, phosphorylation of the steroid receptor coactivator-3 is induced by 17ß-estradiol, leading to increased transcriptional potency of ERs (82). In the absence of estrogens, other signaling pathways, such as the IGF-I and EGF signaling pathways, can modulate the functions of ERs through phosphorylation of the receptors on certain residues (83), as illustrated in Fig. 1.

	CONVERGENCE OF GENOMIC AND NONGENOMIC ACTIONS ON TARGET GENES

TOP ABSTRACT INTRODUCTION ERE-INDEPENDENT GENOMIC ACTIONS NONGENOMIC ACTIONS OF ESTROGENS NONGENOMIC-TO-GENOMIC SIGNALING:... CONVERGENCE OF GENOMIC AND... RESPONSES TO SYNTHETIC LIGANDS CONCLUDING REMARKS REFERENCES

 
The studies described above suggest that ERs can modulate the functions of transcription factors, and in this way regulate gene expression, by at least two distinct mechanisms. These mechanisms are protein-protein interactions in the nucleus and activation of signal transduction pathways at the plasma membrane. These mechanisms function in addition to the classical mechanism of ER action that is extensively reviewed elsewhere (1). Natural gene promoters are often regulated by a large number of transcription factors that bind to distinct regulatory sites. Thus, the possible convergence of genomic and nongenomic actions at multiple response elements provides an extremely fine degree of control for the regulation of transcription by ERs, as illustrated in Fig. 2.

View larger version (56K): [in this window] [in a new window]   Fig. 2. Schematic Illustration of How Genomic and Nongenomic Actions of ERs on a Target Gene Promoter May Converge Nuclear E2-ER complexes bind to EREs, and to transcription factor complexes, e.g. AP-1, STATs, ATF-2 (activation transcription factor 2)/c-Jun, Sp1, and NF-B, that are bound to their cognate DNA binding sites. Membrane E2-ER complexes activate protein-kinase cascades, leading to phosphorylation (P) of target transcription factors, e.g. AP-1, STATs, Elk-1, SRF (serum response factor), CREB, and NF-B. The phosphorylation results in their transcriptional activation and/or in modulation of the transcriptional activities of ER-AP-1, ER-STAT, ER-Sp1, and ER-NF-B complexes at the promoter. Protein-kinase cascades also target ERs themselves and steroid receptor coactivator coactivators, resulting in enhanced transcriptional activity of ERs at EREs. The distinct actions of ERs at multiple response elements provide an extremely fine degree of control for the regulation of target gene transcription.

Regulation of the immediate early c-fos gene by ERs is also mediated through both genomic and nongenomic actions. The interaction of ERs with the Sp1 transcription factor at GC-rich promoter sequences results in activation of the c-fos gene by 17ß-estradiol (21), and this activation also results from activation of the MAPK and PI3-kinase signaling pathways (64, 88). Thus, the nongenomic actions involve activation of both MAPK and PI3-kinase signaling pathways, which target the Elk-1 and the SRF transcription factors, respectively. These transcription factors bind to the SRE located in the c-fos promoter. The c-fos promoter also contains a sis-inducible element recognized by STATs and a cAMP response element, and these may be targets for ERs through both genomic and nongenomic actions.

Estrogens increase the clearance of LDL and they lower plasma LDL cholesterol levels in postmenopausal women, and these may be the mechanisms by which estrogens reduce the risk of cardiovascular disease (89). The LDL-R gene is activated by 17ß-estradiol in the liver, although the LDL-R promoter does not contain any ERE-like sequences (90). It has been reported that the interaction of ERs with the Sp1 transcription factor at GC-rich promoter sequences gives rise to activation of the LDL-R gene by 17ß-estradiol (20). In addition, tyrosine-kinase activity is required for the 17ß-estradiol-induced activation of the LDL-R gene (91), suggesting that nongenomic actions are involved. The tyrosine-kinase pathway may be connected with Sp1-dependent transcription. The LDL-R promoter also contains an SRE and this may be the target for ERs through nongenomic actions that involve activation of the MAPK and PI3-kinase signaling pathways.

Some estrogen-responsive genes contain a combination of direct ER binding sites and binding sites to which ERs indirectly associate through tethering. One such gene is the vascular endothelial growth factor gene that contains a variant ERE that specifically binds ERs activated by 17ß-estradiol, and G/GC-rich sequences that bind ER-Sp1 and ER-Sp3 complexes (92, 93). Furthermore, a number of genes that contain ERE half-sites in proximity to Sp1 binding sites, both of which must be occupied for maximal activation, are activated by 17ß-estradiol. Such genes include those for retinoic acid receptor (94), TGF (95), and progesterone receptor (96).

It is evident that the regulation of gene expression by ERs is a multifactorial process, involving both genomic and nongenomic actions that often converge at certain response elements located in the promoters of target genes. The final gene responses, however, may depend on a number of conditions such as the combination of transcription factors bound to a specific gene promoter, the cellular localization of ERs, the expression levels of various coregulator proteins and signal transduction components, and the nature of extracellular stimuli. These variables are highly specific for the cell type. Thus, estrogens may use different signaling pathways depending on the cellular context, and in this way evoke distinct gene responses in different types of target cells, as illustrated in Fig. 3.

View larger version (37K): [in this window] [in a new window]   Fig. 3. Schematic Illustration of How ERs May Regulate Transcription at a Putative Target Gene Promoter in Different Types of Target Cells The signaling pathways used, i.e. ER actions at EREs or ERE-independent genomic and nongenomic actions of ERs, depend on the cellular localization of ERs, and in this way, the magnitude of the gene response evoked by E2 may differ between target cells.

	RESPONSES TO SYNTHETIC LIGANDS

TOP ABSTRACT INTRODUCTION ERE-INDEPENDENT GENOMIC ACTIONS NONGENOMIC ACTIONS OF ESTROGENS NONGENOMIC-TO-GENOMIC SIGNALING:... CONVERGENCE OF GENOMIC AND... RESPONSES TO SYNTHETIC LIGANDS CONCLUDING REMARKS REFERENCES

It has been suggested that estrogen-responsive genes containing AP-1 binding sites contribute to the difference in response that particular tissues make to selective ER modulators (SERMs). These differences, it is suggested, arise through differences in the activation of ER and ERß in the nucleus (97). Differential activation of ER-Sp1 and of ERß-Sp1 complexes at GC-rich promoters takes place also in the presence of SERMs (98). More recent studies, however, suggest that some of the responses to SERMs are mediated through nongenomic actions, which subsequently lead to genomic responses (70, 99). It may be possible, therefore, to develop of novel tissue-specific drugs that modulate the function of ERs at specific cellular locations.

It has been claimed that estren, a synthetic estrogen, exerts only nongenomic actions (50). However, estren also affects ER actions in the nucleus (70), and it activates transcription at EREs, although the transcriptional potency of estren is lower that of 17ß-estradiol (100).

The full estrogen antagonist ICI 182,780, on the other hand, is unable to exert nongenomic actions mediated through classical receptors, and this antagonist blocks completely the nongenomic actions of estrogens (40, 50, 55, 63, 64, 65, 67, 78). However, ICI 182,780 is a potent agonist to both ER and ERß when the receptors are tethered to the AP-1 (13, 14, 97), Sp1 (98, 101), and STAT5 (29) transcription factors in the nucleus. Thus, not all signaling pathways are inhibited by this antagonist.

	CONCLUDING REMARKS

TOP ABSTRACT INTRODUCTION ERE-INDEPENDENT GENOMIC ACTIONS NONGENOMIC ACTIONS OF ESTROGENS NONGENOMIC-TO-GENOMIC SIGNALING:... CONVERGENCE OF GENOMIC AND... RESPONSES TO SYNTHETIC LIGANDS CONCLUDING REMARKS REFERENCES

 
It is evident that many genes are regulated by ERs and that these genes are of two types: those that contain EREs and those that do not. The latter genes contain binding sites for a variety of heterogeneous transcription factors. ER actions at alternative response elements enable a broader range of genes to be regulated than the range that can be regulated by the classical mechanism of ER action alone. It is important to note that the nongenomic actions of estrogens target many of the transcription factors, such as AP-1, that participate in protein-protein interactions with ERs in the nucleus. The possible convergence of genomic and nongenomic actions on target genes is an attractive mechanism by which ERs can finely regulate gene expression. The relative contributions of genomic and nongenomic actions to certain gene responses in vivo, however, remain to be elucidated. The molecular mechanisms underlying the effects of estrogens are likely to be specific for the cell type, and thus, the gene responses are likely to be diverse.

It appears that different functional domains of ERs are involved in different receptor actions. Thus, naturally occurring splice variants such as ERßcx (102), ERß3 (103), and the 46-kDa ER (47), although unable to regulate transcription at EREs, may act through alternative signaling pathways in their target tissues. If this is the case, it will have important biological significance.

Further knowledge about the molecular mechanisms by which ERs regulate transcription at alternative response elements may enable drug design to target specific receptor actions. Drugs that have been designed to differently affect ER actions at specific cellular locations in a manner that depends on the cell type would widely expand the pharmacological possibilities open to physicians.

	FOOTNOTES

 
First Published Online February 3, 2005

Abbreviations: AF, Activation function; AP-1, activator protein 1; C/EBPß, CCAAT/enhancer binding protein ß; CRE, cAMP response element; CREB, CRE binding protein; DBD, DNA binding domain; EGF, epidermal growth factor; eNOS, endothelial nitric oxide synthase; ER, estrogen receptor; ERE, estrogen response element; LDL, low-density lipoprotein; LDL-R, LDL receptor; NF-ß, nuclear factor ß; PI, phosphoinositol; SERM, selective ER modulators; SRE, serum response element; STAT, signal transducer and activator of transcription.

Received for publication December 7, 2004. Accepted for publication January 25, 2005.

	REFERENCES

TOP ABSTRACT INTRODUCTION ERE-INDEPENDENT GENOMIC ACTIONS NONGENOMIC ACTIONS OF ESTROGENS NONGENOMIC-TO-GENOMIC SIGNALING:... CONVERGENCE OF GENOMIC AND... RESPONSES TO SYNTHETIC LIGANDS CONCLUDING REMARKS REFERENCES

 

1. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA 2001 Mechanisms of estrogen action. Physiol Rev 81:1535–1565[Abstract/Free Full Text]
2. Rosenfeld MG, Glass CK 2001 Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276:36865–36868[Free Full Text]
3. O’Lone R, Frith MC, Karlsson EK, Hansen U 2004 Genomic targets of nuclear estrogen receptors. Mol Endocrinol 18:1859–1875[Abstract/Free Full Text]
4. Gottlicher M, Heck S, Herrlich P 1998 Transcriptional cross-talk, the second mode of steroid hormone receptor action. J Mol Med 76:480–489[CrossRef][Medline]
5. Vanacker JM, Pettersson K, Gustafsson JA, Laudet V 1999 Transcriptional targets shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER) , but not by ERß. EMBO J 18:4270–4279[CrossRef][Medline]
6. Losel R, Wehling M 2003 Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 4:46–56[CrossRef][Medline]
7. Gaub MP, Bellard M, Scheuer I, Chambon P, Sassone-Corsi P 1990 Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell 63:1267–1276[CrossRef][Medline]
8. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y, Kamada T 1994 Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 269:16433–16442[Abstract/Free Full Text]
9. Webb P, Lopez GN, Uht RM, Kushner PJ 1995 Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9:443–456[Abstract/Free Full Text]
10. Sabbah M, Courilleau D, Mester J, Redeuilh G 1999 Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Natl Acad Sci USA 96:11217–11222[Abstract/Free Full Text]
11. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price Jr RH, Pestell RG, Kushner PJ 2002 Opposing action of estrogen receptors and ß on cyclin D1 gene expression. J Biol Chem 277:24353–24360[Abstract/Free Full Text]
12. Philips A, Teyssier C, Galtier F, Rivier-Covas C, Rey JM, Rochefort H, Chalbos D 1998 FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. Mol Endocrinol 12:973–985[Abstract/Free Full Text]
13. Jakacka M, Ito M, Weiss J, Chien PY, Gehm BD, Jameson JL 2001 Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J Biol Chem 276:13615–13621[Abstract/Free Full Text]
14. Björnström L, Sjöberg M 2002 Mutations in the estrogen receptor DNA-binding domain discriminate between the classical mechanism of action and cross-talk with Stat5b and activating protein 1 (AP-1). J Biol Chem 277:48479–48483[Abstract/Free Full Text]
15. Schmitt M, Bausero P, Simoni P, Queuche D, Geoffroy V, Marschal C, Kempf J, Quirin-Stricker C 1995 Positive and negative effects of nuclear receptors on transcription activation by AP-1 of the human choline acetyltransferase proximal promoter. J Neurosci Res 40:152–164[CrossRef][Medline]
16. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P 2000 Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74:311–317[CrossRef][Medline]
17. Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S, Kushner PJ 1999 The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 13:1672–1685[Abstract/Free Full Text]
18. Teyssier C, Belguise K, Galtier F, Chalbos D 2001 Characterization of the physical interaction between estrogen receptor and JUN proteins. J Biol Chem 276:36361–36369[Abstract/Free Full Text]
19. Porter W, Saville B, Hoivik D, Safe S 1997 Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 11:1569–1580[Abstract/Free Full Text]
20. Li C, Briggs MR, Ahlborn TE, Kraemer FB, Liu J 2001 Requirement of Sp1 and estrogen receptor interaction in 17ß-estradiol-mediated transcriptional activation of the low density lipoprotein receptor gene expression. Endocrinology 142:1546–1553[Abstract/Free Full Text]
21. Duan R, Porter W, Safe S 1998 Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology 139:1981–1990[Abstract/Free Full Text]
22. Castro-Rivera E, Samudio I, Safe S 2001 Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem 276:30853–30861[Abstract/Free Full Text]
23. Safe S 2001 Transcriptional activation of genes by 17 ß-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 62:231–252[Medline]
24. Ray A, Prefontaine KE, Ray P 1994 Down-modulation of interleukin-6 gene expression by 17 ß-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem 269:12940–12946[Abstract/Free Full Text]
25. Stein B, Yang MX 1995 Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-B and C/EBP ß. Mol Cell Biol 15:4971–4979[Abstract]
26. Blobel GA, Sieff CA, Orkin SH 1995 Ligand-dependent repression of the erythroid transcription factor GATA-1 by the estrogen receptor. Mol Cell Biol 15:3147–3153[Abstract]
27. Stoecklin E, Wissler M, Schaetzle D, Pfitzner E, Groner B 1999 Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. J Steroid Biochem Mol Biol 69:195–204[CrossRef][Medline]
28. Faulds MH, Pettersson K, Gustafsson JA, Haldosen LA 2001 Cross-talk between ERs and signal transducer and activator of transcription 5 is E2 dependent and involves two functionally separate mechanisms. Mol Endocrinol 15:1929–1940[Abstract/Free Full Text]
29. Björnström L, Kilic E, Norman M, Parker MG, Sjöberg M 2001 Cross-talk between Stat5b and estrogen receptor- and -ß in mammary epithelial cells. J Mol Endocrinol 27:93–106[Abstract]
30. Heck S, Kullmann M, Gast A, Ponta H, Rahmsdorf HJ, Herrlich P, Cato AC 1994 A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J 13:4087–4095[Medline]
31. Improta-Brears T, Whorton AR, Codazzi F, York JD, Meyer T, McDonnell DP 1999 Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc Natl Acad Sci USA 96:4686–4691[Abstract/Free Full Text]
32. Aronica SM, Kraus WL, Katzenellenbogen BS 1994 Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci USA 91:8517–8521[Abstract/Free Full Text]
33. Razandi M, Pedram A, Greene GL, Levin ER 1999 Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ER and ERß expressed in Chinese hamster ovary cells. Mol Endocrinol 13:307–319[Abstract/Free Full Text]
34. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F 1996 Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15:1292–1300[Medline]
35. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW 1999 Estrogen receptor mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 103:401–406[Medline]
36. Endoh H, Sasaki H, Maruyama K, Takeyama K, Waga I, Shimizu T, Kato S, Kawashima H 1997 Rapid activation of MAP kinase by estrogen in the bone cell line. Biochem Biophys Res Commun 235:99–102[CrossRef][Medline]
37. Jessop HL, Sjoberg M, Cheng MZ, Zaman G, Wheeler-Jones CP, Lanyon LE 2001 Mechanical strain and estrogen activate estrogen receptor in bone cells. J Bone Miner Res 16:1045–1055[CrossRef][Medline]
38. Watters JJ, Campbell JS, Cunningham MJ, Krebs EG, Dorsa DM 1997 Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 138:4030–4033[Abstract/Free Full Text]
39. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV, Auricchio F 2001 PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 20:6050–6059[CrossRef][Medline]
40. Marino M, Acconcia F, Bresciani F, Weisz A, Trentalance A 2002 Distinct nongenomic signal transduction pathways controlled by 17ß-estradiol regulate DNA synthesis and cyclin D(1) gene transcription in HepG2 cells. Mol Biol Cell 13:3720–3729[Abstract/Free Full Text]
41. Pappas TC, Gametchu B, Watson CS 1995 Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J 9:404–410[Abstract/Free Full Text]
42. Toran-Allerand CD, Guan X, MacLusky NJ, Horvath TL, Diano S, Singh M, Connolly Jr ES, Nethrapalli IS, Tinnikov AA 2002 ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J Neurosci 22:8391–8401[Abstract/Free Full Text]
43. Kim HP, Lee JY, Jeong JK, Bae SW, Lee HK, Jo I 1999 Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor localized in caveolae. Biochem Biophys Res Commun 263:257–262[CrossRef][Medline]
44. Chambliss KL, Yuhanna IS, Mineo C, Liu P, German Z, Sherman TS, Mendelsohn ME, Anderson RG, Shaul PW 2000 Estrogen receptor and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ Res 87:E44–E52
45. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW 2002 ERß has nongenomic action in caveolae. Mol Endocrinol 16:938–946[Abstract/Free Full Text]
46. Shaul PW, Anderson RG 1998 Role of plasmalemmal caveolae in signal transduction. Am J Physiol 275:L843–L851
47. Li L, Haynes MP, Bender JR 2003 Plasma membrane localization and function of the estrogen receptor variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 100:4807–4812[Abstract/Free Full Text]
48. Acconcia F, Ascenzi P, Fabozzi G, Visca P, Marino M 2004 S-Palmitoylation modulates human estrogen receptor- functions. Biochem Biophys Res Commun 316:878–883[CrossRef][Medline]
49. Razandi M, Pedram A, Merchenthaler I, Greene GL, Levin ER 2004 Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol 18:2854–2865[Abstract/Free Full Text]
50. Kousteni S, Bellido T, Plotkin LI, O’Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC 2001 Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104:719–730[Medline]
51. Razandi M, Oh P, Pedram A, Schnitzer J, Levin ER 2002 ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol 16:100–115[Abstract/Free Full Text]
52. Wyckoff MH, Chambliss KL, Mineo C, Yuhanna IS, Mendelsohn ME, Mumby SM, Shaul PW 2001 Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through G(i). J Biol Chem 276:27071–27076[Abstract/Free Full Text]
53. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M, Auricchio F 1998 Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 17:2008–2018[CrossRef][Medline]
54. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK 2000 Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538–541[CrossRef][Medline]
55. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ 2002 Linkage of rapid estrogen action to MAPK activation by ER-Shc association and Shc pathway activation. Mol Endocrinol 16:116–127[Abstract/Free Full Text]
56. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ 2002 Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 99:14783–14788[Abstract/Free Full Text]
57. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C 2000 Estrogen receptor rapidly activates the IGF-1 receptor pathway. J Biol Chem 275:18447–18453[Abstract/Free Full Text]
58. Chung YL, Sheu ML, Yang SC, Lin CH, Yen SH 2002 Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 97:306–312[CrossRef][Medline]
59. Razandi M, Pedram A, Park ST, Levin ER, Oh P, Schnitzer J 2003 Proximal events in signaling by plasma membrane estrogen receptors ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. J Biol Chem 278:2701–2712[Abstract/Free Full Text]
60. Cruzalegui FH, Cano E, Treisman R 1999 ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry. Oncogene 18:7948–7957[CrossRef][Medline]
61. Buck M, Poli V, van der Geer P, Chojkier M, Hunter T 1999 Phosphorylation of rat serine 105 or mouse threonine 217 in C/EBP ß is required for hepatocyte proliferation induced by TGF . Mol Cell 4:1087–1092[CrossRef][Medline]
62. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME 1999 Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286:1358–1362[Abstract/Free Full Text]
63. de Jager T, Pelzer T, Muller-Botz S, Imam A, Muck J, Neyses L 2001 Mechanisms of estrogen receptor action in the myocardium. Rapid gene activation via the ERK1/2 pathway and serum response elements. J Biol Chem 276:27873–27880[Abstract/Free Full Text]
64. Duan R, Xie W, Burghardt RC, Safe S 2001 Estrogen receptor-mediated activation of the serum response element in MCF-7 cells through MAPK-dependent phosphorylation of Elk-1. J Biol Chem 276:11590–11598[Abstract/Free Full Text]
65. Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, Bellido T, Manolagas SC 2003 Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 111:1651–1664[CrossRef][Medline]
66. Zhou Y, Watters JJ, Dorsa DM 1996 Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology 137:2163–2166[Abstract]
67. Dos Santos EG, Dieudonne MN, Pecquery R, Le Moal V, Giudicelli Y, Lacasa D 2002 Rapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and cAMP response element binding protein in rat white adipocytes. Endocrinology 143:930–940[Abstract/Free Full Text]
68. Shaywitz AJ, Greenberg ME 1999 CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68:821–861[CrossRef][Medline]
69. Karin M 1995 The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270:16483–16486[Free Full Text]
70. Björnström L, Sjöberg M 2004 Estrogen receptor-dependent activation of AP-1 via non-genomic signalling. Nucl Recept 2:3[CrossRef][Medline]
71. Caelles C, Gonzalez-Sancho JM, Munoz A 1997 Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev 11:3351–3364[Abstract/Free Full Text]
72. Gonzalez MV, Jimenez B, Berciano MT, Gonzalez-Sancho JM, Caelles C, Lafarga M, Munoz A 2000 Glucocorticoids antagonize AP-1 by inhibiting the Activation/phosphorylation of JNK without affecting its subcellular distribution. J Cell Biol 150:1199–1208[Abstract/Free Full Text]
73. Romashkova JA, Makarov SS 1999 NF-B is a target of AKT in anti-apoptotic PDGF signalling. Nature 401:86–90[CrossRef][Medline]
74. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB 1999 NF-B activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401:82–85[CrossRef][Medline]
75. Kawagoe J, Ohmichi M, Takahashi T, Ohshima C, Mabuchi S, Takahashi K, Igarashi H, Mori-Abe A, Saitoh M, Du B, Ohta T, Kimura A, Kyo S, Inoue M, Kurachi H 2003 Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line. J Biol Chem 278:43363–43372[Abstract/Free Full Text]
76. Darnell Jr JE 1997 STATs and gene regulation. Science 277:1630–1635[Abstract/Free Full Text]
77. Decker T, Kovarik P 2000 Serine phosphorylation of STATs. Oncogene 19:2628–2637[CrossRef][Medline]
78. Björnström L, Sjöberg M 2002 Signal transducers and activators of transcription as downstream targets of nongenomic estrogen receptor actions. Mol Endocrinol 16:2202–2214[Abstract/Free Full Text]
79. Wyszomierski SL, Yeh J, Rosen JM 1999 Glucocorticoid receptor/signal transducer and activator of transcription 5 (STAT5) interactions enhance STAT5 activation by prolonging STAT5 DNA binding and tyrosine phosphorylation. Mol Endocrinol 13:330–343[Abstract/Free Full Text]
80. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491–1494[Abstract/Free Full Text]
81. Tremblay A, Tremblay GB, Labrie F, Giguere V 1999 Ligand-independent recruitment of SRC-1 to estrogen receptor ß through phosphorylation of activation function AF-1. Mol Cell 3:513–519[CrossRef][Medline]
82. Wu RC, Qin J, Yi P, Wong J, Tsai SY, Tsai MJ, O’Malley BW 2004 Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell 15:937–949[CrossRef][Medline]
83. Driggers PH, Segars JH 2002 Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab 13:422–427[CrossRef][Medline]
84. Planas-Silva MD, Weinberg RA 1997 Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 17:4059–4069[Abstract]
85. Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL 1997 Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272:10882–10894[Abstract/Free Full Text]
86. Herber B, Truss M, Beato M, Muller R 1994 Inducible regulatory elements in the human cyclin D1 promoter. Oncogene 9:2105–2107[Medline]
87. Shiozawa T, Miyamoto T, Kashima H, Nakayama K, Nikaido T, Konishi I 2004 Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence. Oncogene 23:8603–8610[CrossRef][Medline]
88. Duan R, Xie W, Li X, McDougal A, Safe S 2002 Estrogen regulation of c-fos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cells. Biochem Biophys Res Commun 294:384–394[CrossRef][Medline]
89. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM 1991 Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325:1196–1204[Abstract]
90. Croston GE, Milan LB, Marschke KB, Reichman M, Briggs MR 1997 Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes. Endocrinology 138:3779–3786[Abstract/Free Full Text]
91. Distefano E, Marino M, Gillette JA, Hanstein B, Pallottini V, Bruning J, Krone W, Trentalance A 2002 Role of tyrosine kinase signaling in estrogen-induced LDL receptor gene expression in HepG2 cells. Biochim Biophys Acta 1580:145–149[Medline]
92. Mueller MD, Vigne JL, Minchenko A, Lebovic DI, Leitman DC, Taylor RN 2000 Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors and ß. Proc Natl Acad Sci USA 97:10972–10977[Abstract/Free Full Text]
93. Stoner M, Wang F, Wormke M, Nguyen T, Samudio I, Vyhlidal C, Marme D, Finkenzeller G, Safe S 2000 Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor and Sp3 proteins. J Biol Chem 275:22769–22779[Abstract/Free Full Text]
94. Rishi AK, Shao ZM, Baumann RG, Li XS, Sheikh MS, Kimura S, Bashirelahi N, Fontana JA 1995 Estradiol regulation of the human retinoic acid receptor gene in human breast carcinoma cells is mediated via an imperfect half-palindromic estrogen response element and Sp1 motifs. Cancer Res 55:4999–5006[Abstract/Free Full Text]
95. Vyhlidal C, Samudio I, Kladde MP, Safe S 2000 Transcriptional activation of transforming growth factor by estradiol: requirement for both a GC-rich site and an estrogen response element half-site. J Mol Endocrinol 24:329–338[Abstract]
96. Petz LN, Nardulli AM 2000 Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. Mol Endocrinol 14:972–985[Abstract/Free Full Text]
97. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS 1997 Differential ligand activation of estrogen receptors ER and ERß at AP1 sites. Science 277:1508–1510[Abstract/Free Full Text]
98. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson JA, Safe S 2000 Ligand-, cell-, and estrogen receptor subtype (/ß)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 275:5379–5387[Abstract/Free Full Text]
99. Singleton DW, Feng Y, Burd CJ, Khan SA 2003 Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells. Endocrinology 144:121–128[Abstract/Free Full Text]
100. Moverare S, Dahllund J, Andersson N, Islander U, Carlsten H, Gustafsson JA, Nilsson S, Ohlsson C 2003 Estren is a selective estrogen receptor modulator with transcriptional activity. Mol Pharmacol 64:1428–1433[Abstract/Free Full Text]
101. Zou A, Marschke KB, Arnold KE, Berger EM, Fitzgerald P, Mais DE, Allegretto EA 1999 Estrogen receptor ß activates the human retinoic acid receptor -1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. Mol Endocrinol 13:418–430[Abstract/Free Full Text]
102. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M 1998 Molecular cloning and characterization of human estrogen receptor ßcx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26:3505–3512[Abstract/Free Full Text]
103. Price Jr RH, Butler CA, Webb P, Uht R, Kushner P, Handa RJ 2001 A splice variant of estrogen receptor ß missing exon 3 displays altered subnuclear localization and capacity for transcriptional activation. Endocrinology 142:2039–2049[Abstract/Free Full Text]

NURSA Molecule Pages Link:

Nuclear Receptors:   ERα  |  ERβ

Coregulators:   STAT3  |  CAV1  |  PELP1

Ligands:   17β-Estradiol

This article has been cited by other articles:

				S.-Y. Kim, J. Weiss, M. Tong, M. M. Laronda, E.-J. Lee, and J. L. Jameson Foxl2, a Forkhead Transcription Factor, Modulates Nonclassical Activity of the Estrogen Receptor-{alpha} Endocrinology, November 1, 2009; 150(11): 5085 - 5093. [Abstract] [Full Text] [PDF]

				P. Galluzzo, C. Rastelli, P. Bulzomi, F. Acconcia, V. Pallottini, and M. Marino 17{beta}-Estradiol regulates the first steps of skeletal muscle cell differentiation via ER-{alpha}-mediated signals Am J Physiol Cell Physiol, November 1, 2009; 297(5): C1249 - C1262. [Abstract] [Full Text] [PDF]

				E. R. Levin Membrane oestrogen receptor \#945; signalling to cell functions J. Physiol., November 1, 2009; 587(21): 5019 - 5023. [Abstract] [Full Text] [PDF]

				J. Chen, J. K. Saggar, P. Corey, and L. U. Thompson Flaxseed and Pure Secoisolariciresinol Diglucoside, but Not Flaxseed Hull, Reduce Human Breast Tumor Growth (MCF-7) in Athymic Mice J. Nutr., November 1, 2009; 139(11): 2061 - 2066. [Abstract] [Full Text] [PDF]

				M. Koslowski, O. Tureci, S. Biesterfeld, G. Seitz, C. Huber, and U. Sahin Selective Activation of Trophoblast-specific PLAC1 in Breast Cancer by CCAAT/Enhancer-binding Protein {beta} (C/EBP{beta}) Isoform 2 J. Biol. Chem., October 16, 2009; 284(42): 28607 - 28615. [Abstract] [Full Text] [PDF]

				I. I. Park, Q. Zhang, V. Liu, J. M. Kozlowski, J. Zhang, and C. Lee 17{beta}-Estradiol at Low Concentrations Acts through Distinct Pathways in Normal Versus Benign Prostatic Hyperplasia-Derived Prostate Stromal Cells Endocrinology, October 1, 2009; 150(10): 4594 - 4605. [Abstract] [Full Text] [PDF]

				H. Chen, K. Yang, S. Choi, J. H. Fischer, and H. Jeong Up-Regulation of UDP-Glucuronosyltransferase (UGT) 1A4 by 17{beta}-Estradiol: A Potential Mechanism of Increased Lamotrigine Elimination in Pregnancy Drug Metab. Dispos., September 1, 2009; 37(9): 1841 - 1847. [Abstract] [Full Text] [PDF]

				S. C. Wu and Y. Zhang Minireview: Role of Protein Methylation and Demethylation in Nuclear Hormone Signaling Mol. Endocrinol., September 1, 2009; 23(9): 1323 - 1334. [Abstract] [Full Text] [PDF]

				L. Shi, B. Dong, Z. Li, Y. Lu, T. Ouyang, J. Li, T. Wang, Z. Fan, T. Fan, B. Lin, et al. Expression of ER-{alpha}36, a Novel Variant of Estrogen Receptor {alpha}, and Resistance to Tamoxifen Treatment in Breast Cancer J. Clin. Oncol., July 20, 2009; 27(21): 3423 - 3429. [Abstract] [Full Text] [PDF]

				S. L. Nott, Y. Huang, X. Li, B. R. Fluharty, X. Qiu, W. V. Welshons, S. Yeh, and M. Muyan Genomic Responses from the Estrogen-responsive Element-dependent Signaling Pathway Mediated by Estrogen Receptor {alpha} Are Required to Elicit Cellular Alterations J. Biol. Chem., May 29, 2009; 284(22): 15277 - 15288. [Abstract] [Full Text] [PDF]

				E. Ohashi, T. Kogai, H. Kagechika, and G. A. Brent Activation of the PI3 Kinase Pathway By Retinoic Acid Mediates Sodium/Iodide Symporter Induction and Iodide Transport in MCF-7 Breast Cancer Cells Cancer Res., April 15, 2009; 69(8): 3443 - 3450. [Abstract] [Full Text] [PDF]

				J. Keay and J. W. Thornton Hormone-Activated Estrogen Receptors in Annelid Invertebrates: Implications for Evolution and Endocrine Disruption Endocrinology, April 1, 2009; 150(4): 1731 - 1738. [Abstract] [Full Text] [PDF]

				A. Pedram, M. Razandi, J. K Kim, F. O'Mahony, E. Y. Lee, U. Luderer, and E. R. Levin Developmental Phenotype of a Membrane Only Estrogen Receptor {alpha} (MOER) Mouse J. Biol. Chem., February 6, 2009; 284(6): 3488 - 3495. [Abstract] [Full Text] [PDF]

				S. A. Ochsner, D. L. Steffen, S. G. Hilsenbeck, E. S. Chen, C. Watkins, and N. J. McKenna GEMS (Gene Expression Metasignatures), a Web Resource for Querying Meta-analysis of Expression Microarray Datasets: 17{beta}-Estradiol in MCF-7 Cells Cancer Res., January 1, 2009; 69(1): 23 - 26. [Abstract] [Full Text] [PDF]

				M. Rotinen, J. Celay, M. M Alonso, A. Arrazola, I. Encio, and J. Villar Estradiol induces type 8 17{beta}-hydroxysteroid dehydrogenase expression: crosstalk between estrogen receptor {alpha} and C/EBP{beta} J. Endocrinol., January 1, 2009; 200(1): 85 - 92. [Abstract] [Full Text] [PDF]

				Y. Katsu, S. Kohno, S. Hyodo, S. Ijiri, S. Adachi, A. Hara, L. J. Guillette Jr., and T. Iguchi Molecular Cloning, Characterization, and Evolutionary Analysis of Estrogen Receptors from Phylogenetically Ancient Fish Endocrinology, December 1, 2008; 149(12): 6300 - 6310. [Abstract] [Full Text] [PDF]

				K. K. Schnoes, I. Z. Jaffe, L. Iyer, A. Dabreo, M. Aronovitz, B. Newfell, U. Hansen, G. Rosano, and M. E. Mendelsohn Research Resource: Rapid Recruitment of Temporally Distinct Vascular Gene Sets by Estrogen Mol. Endocrinol., November 1, 2008; 22(11): 2544 - 2556. [Abstract] [Full Text] [PDF]

				S. Xu, Y. Cheng, J. R. Keast, and P. B. Osborne 17{beta}-Estradiol Activates Estrogen Receptor {beta}-Signalling and Inhibits Transient Receptor Potential Vanilloid Receptor 1 Activation by Capsaicin in Adult Rat Nociceptor Neurons Endocrinology, November 1, 2008; 149(11): 5540 - 5548. [Abstract] [Full Text] [PDF]

				E. R. Levin Rapid signaling by steroid receptors Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2008; 295(5): R1425 - R1430. [Abstract] [Full Text] [PDF]

				T. W. Bonagura, G. J. Pepe, A. C. Enders, and E. D. Albrecht Suppression of Extravillous Trophoblast Vascular Endothelial Growth Factor Expression and Uterine Spiral Artery Invasion by Estrogen during Early Baboon Pregnancy Endocrinology, October 1, 2008; 149(10): 5078 - 5087. [Abstract] [Full Text] [PDF]

				F. Yasuhara, G. R. O. Gomes, E. R. Siu, C. I. Suenaga, E. Marostica, C. S. Porto, and M. F. M. Lazari Effects of the Antiestrogen Fulvestrant (ICI 182,780) on Gene Expression of the Rat Efferent Ductules Biol Reprod, September 1, 2008; 79(3): 432 - 441. [Abstract] [Full Text] [PDF]

				L. Albanito, D. Sisci, S. Aquila, E. Brunelli, A. Vivacqua, A. Madeo, R. Lappano, D. P. Pandey, D. Picard, L. Mauro, et al. Epidermal Growth Factor Induces G Protein-Coupled Receptor 30 Expression in Estrogen Receptor-Negative Breast Cancer Cells Endocrinology, August 1, 2008; 149(8): 3799 - 3808. [Abstract] [Full Text] [PDF]

				A. Grasselli, S. Nanni, C. Colussi, A. Aiello, V. Benvenuti, G. Ragone, F. Moretti, A. Sacchi, S. Bacchetti, C. Gaetano, et al. Estrogen Receptor-{alpha} and Endothelial Nitric Oxide Synthase Nuclear Complex Regulates Transcription of Human Telomerase Circ. Res., July 3, 2008; 103(1): 34 - 42. [Abstract] [Full Text] [PDF]

				A. P. Kouzmenko, K.-i. Takeyama, Y. Kawasaki, T. Akiyama, and S. Kato Ligand-dependent interaction between estrogen receptor alpha and adenomatous polyposis coli. Genes Cells, July 1, 2008; 13(7): 723 - 730. [Abstract] [Full Text] [PDF]

				X. Long, M. Fan, R. M. Bigsby, and K. P. Nephew Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-{alpha}-dependent and estrogen receptor-{alpha}-independent mechanisms Mol. Cancer Ther., July 1, 2008; 7(7): 2096 - 2108. [Abstract] [Full Text] [PDF]

				D. Titolo, C. M. Mayer, S. S. Dhillon, F. Cai, and D. D. Belsham Estrogen Facilitates both Phosphatidylinositol 3-Kinase/Akt and ERK1/2 Mitogen-Activated Protein Kinase Membrane Signaling Required for Long-Term Neuropeptide Y Transcriptional Regulation in Clonal, Immortalized Neurons J. Neurosci., June 18, 2008; 28(25): 6473 - 6482. [Abstract] [Full Text] [PDF]

				C. Dimple, S. S. Nair, R. Rajhans, P. R. Pitcheswara, J. Liu, S. Balasenthil, X.-F. Le, M. E. Burow, N. Auersperg, R. R. Tekmal, et al. Role of PELP1/MNAR Signaling in Ovarian Tumorigenesis Cancer Res., June 15, 2008; 68(12): 4902 - 4909. [Abstract] [Full Text] [PDF]

				Z. Zeng, M. C. Velarde, F. A. Simmen, and R. C.M. Simmen Delayed Parturition and Altered Myometrial Progesterone Receptor Isoform A Expression in Mice Null for Kruppel-Like Factor 9 Biol Reprod, June 1, 2008; 78(6): 1029 - 1037. [Abstract] [Full Text] [PDF]

				J. K. Nagpal, S. Nair, D. Chakravarty, R. Rajhans, S. Pothana, D. W. Brann, R. R. Tekmal, and R. K. Vadlamudi Growth Factor Regulation of Estrogen Receptor Coregulator PELP1 Functions via Protein Kinase A Pathway Mol. Cancer Res., May 1, 2008; 6(5): 851 - 861. [Abstract] [Full Text] [PDF]

				R. Rajhans, H. B. Nair, S. S. Nair, V. Cortez, K. Ikuko, N. B. Kirma, D. Zhou, A. E. Holden, D. W Brann, S. Chen, et al. Modulation of in Situ Estrogen Synthesis by Proline-, Glutamic Acid-, and Leucine-Rich Protein-1: Potential Estrogen Receptor Autocrine Signaling Loop in Breast Cancer Cells Mol. Endocrinol., March 1, 2008; 22(3): 649 - 664. [Abstract] [Full Text] [PDF]

				M. Guix, N. de Matos Granja, I. Meszoely, T. B. Adkins, B. M. Wieman, K. E. Frierson, V. Sanchez, M. E. Sanders, A. M. Grau, I. A. Mayer, et al. Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor-Positive Breast Cancers J. Clin. Oncol., February 20, 2008; 26(6): 897 - 906. [Abstract] [Full Text] [PDF]

				Y. Liu, H. Gao, T. T. Marstrand, A. Strom, E. Valen, A. Sandelin, J.-A. Gustafsson, and K. Dahlman-Wright The genome landscape of ER{alpha}- and ER{beta}-binding DNA regions PNAS, February 19, 2008; 105(7): 2604 - 2609. [Abstract] [Full Text] [PDF]

				A. Vasconsuelo, L. Milanesi, and R. Boland 17{beta}-Estradiol abrogates apoptosis in murine skeletal muscle cells through estrogen receptors: role of the phosphatidylinositol 3-kinase/Akt pathway J. Endocrinol., February 1, 2008; 196(2): 385 - 397. [Abstract] [Full Text] [PDF]

				Y. Katsu, R. Ichikawa, T. Ikeuchi, S. Kohno, L. J. Guillette Jr., and T. Iguchi Molecular Cloning and Characterization of Estrogen, Androgen, and Progesterone Nuclear Receptors from a Freshwater Turtle (Pseudemys nelsoni) Endocrinology, January 1, 2008; 149(1): 161 - 173. [Abstract] [Full Text] [PDF]

				T. F.G Lucas, E. R Siu, C. A Esteves, H. P Monteiro, C. A Oliveira, C. S Porto, and M. F. M Lazari 17Beta-Estradiol Induces the Translocation of the Estrogen Receptors ESR1 and ESR2 to the Cell Membrane, MAPK3/1 Phosphorylation and Proliferation of Cultured Immature Rat Sertoli Cells Biol Reprod, January 1, 2008; 78(1): 101 - 114. [Abstract] [Full Text] [PDF]

				N. Zhu and U. Hansen HMGN1 Modulates Estrogen-Mediated Transcriptional Activation through Interactions with Specific DNA-Binding Transcription Factors Mol. Cell. Biol., December 15, 2007; 27(24): 8859 - 8873. [Abstract] [Full Text] [PDF]

				K. Britt, A. Ashworth, and M. Smalley Pregnancy and the risk of breast cancer Endocr. Relat. Cancer, December 1, 2007; 14(4): 907 - 933. [Abstract] [Full Text] [PDF]

				M. De los Santos, O. Martinez-Iglesias, and A. Aranda Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells Endocr. Relat. Cancer, December 1, 2007; 14(4): 1021 - 1028. [Abstract] [Full Text] [PDF]

				S. R. Hammes and E. R. Levin Extranuclear Steroid Receptors: Nature and Actions Endocr. Rev., December 1, 2007; 28(7): 726 - 741. [Abstract] [Full Text] [PDF]

				M. C. Velarde, Z. Zeng, J. R. McQuown, F. A. Simmen, and R. C. M. Simmen Kruppel-Like Factor 9 Is a Negative Regulator of Ligand-Dependent Estrogen Receptor {alpha} Signaling in Ishikawa Endometrial Adenocarcinoma Cells Mol. Endocrinol., December 1, 2007; 21(12): 2988 - 3001. [Abstract] [Full Text] [PDF]

				S. H. Windahl, M. K. Lagerquist, N. Andersson, C. Jochems, A. Kallkopf, C. Hakansson, J. Inzunza, J.-A. Gustafsson, P. T. van der Saag, H. Carlsten, et al. Identification of Target Cells for the Genomic Effects of Estrogens in Bone Endocrinology, December 1, 2007; 148(12): 5688 - 5695. [Abstract] [Full Text] [PDF]

				P.-A. Scott, A. Tremblay, M. Brochu, and J. St-Louis Vasorelaxant action of 17 -estradiol in rat uterine arteries: role of nitric oxide synthases and estrogen receptors Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3713 - H3719. [Abstract] [Full Text] [PDF]

				S. C. J. P. Gielen, L. A. M. Santegoets, L. C. M. Kuhne, W. F. J. Van IJcken, B. Boers-Sijmons, P. Hanifi-Moghaddam, T. J. M. Helmerhorst, L. J. Blok, and C. W. Burger Genomic and Nongenomic Effects of Estrogen Signaling in Human Endometrial Cells: Involvement of the Growth Factor Receptor Signaling Downstream AKT Pathway Reproductive Sciences, October 1, 2007; 14(7): 646 - 654. [Abstract] [PDF]

				J. Jiang, N. Sarwar, D. Peston, E. Kulinskaya, S. Shousha, R. C. Coombes, and S. Ali Phosphorylation of Estrogen Receptor-{alpha} at Ser167 Is Indicative of Longer Disease-Free and Overall Survival in Breast Cancer Patients Clin. Cancer Res., October 1, 2007; 13(19): 5769 - 5776. [Abstract] [Full Text] [PDF]

				P. Kundu, A. Alioua, E. Stefani, and L. Toro Regulation of Mouse Slo Gene Expression: MULTIPLE PROMOTERS, TRANSCRIPTION START SITES, AND GENOMIC ACTION OF ESTROGEN J. Biol. Chem., September 14, 2007; 282(37): 27478 - 27492. [Abstract] [Full Text] [PDF]

				G. P Risbridger, S. J Ellem, and S. J McPherson Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling J. Mol. Endocrinol., September 1, 2007; 39(3): 183 - 188. [Abstract] [Full Text] [PDF]

				J. Chen, K. A. Power, J. Mann, A. Cheng, and L. U. Thompson Flaxseed Alone or in Combination with Tamoxifen Inhibits MCF-7 Breast Tumor Growth in Ovariectomized Athymic Mice with High Circulating Levels of Estrogen Experimental Biology and Medicine, September 1, 2007; 232(8): 1071 - 1080. [Abstract] [Full Text] [PDF]

				R. J. Pietras and D. C. Marquez-Garban Membrane-Associated Estrogen Receptor Signaling Pathways in Human Cancers Clin. Cancer Res., August 15, 2007; 13(16): 4672 - 4676. [Full Text] [PDF]

				D. Nonclercq, F. Journe, I. Laios, C. Chaboteaux, R.-A. Toillon, G. Leclercq, and G. Laurent Effect of nuclear export inhibition on estrogen receptor regulation in breast cancer cells J. Mol. Endocrinol., August 1, 2007; 39(2): 105 - 118. [Abstract] [Full Text] [PDF]

				S. Dziennis, T. Jia, O. K. Ronnekleiv, P. D. Hurn, and N. J. Alkayed Role of Signal Transducer and Activator of Transcription-3 in Estradiol-Mediated Neuroprotection J. Neurosci., July 4, 2007; 27(27): 7268 - 7274. [Abstract] [Full Text] [PDF]

				C. M. Silva and M. A. Shupnik Integration of Steroid and Growth Factor Pathways in Breast Cancer: Focus on Signal Transducers and Activators of Transcription and Their Potential Role in Resistance Mol. Endocrinol., July 1, 2007; 21(7): 1499 - 1512. [Abstract] [Full Text] [PDF]

				B. C. Trainor, S. Lin, M. S. Finy*, M. R. Rowland, and R. J. Nelson Photoperiod reverses the effects of estrogens on male aggression via genomic and nongenomic pathways PNAS, June 5, 2007; 104(23): 9840 - 9845. [Abstract] [Full Text] [PDF]

				R. O'Lone, K. Knorr, I. Z. Jaffe, M. E. Schaffer, P. G. V. Martini, R. H. Karas, J. Bienkowska, M. E. Mendelsohn, and U. Hansen Estrogen Receptors {alpha} and {beta} Mediate Distinct Pathways of Vascular Gene Expression, Including Genes Involved in Mitochondrial Electron Transport and Generation of Reactive Oxygen Species Mol. Endocrinol., June 1, 2007; 21(6): 1281 - 1296. [Abstract] [Full Text] [PDF]

				M. E. Wierman and W. M. Kohrt Review Article: Vascular and Metabolic Effects of Sex Steroids: New Insights Into Clinical Trials Reproductive Sciences, May 1, 2007; 14(4): 300 - 314. [Abstract] [PDF]

				A. A. Kazi and R. D. Koos Estrogen-Induced Activation of Hypoxia-Inducible Factor-1{alpha}, Vascular Endothelial Growth Factor Expression, and Edema in the Uterus Are Mediated by the Phosphatidylinositol 3-Kinase/Akt Pathway Endocrinology, May 1, 2007; 148(5): 2363 - 2374. [Abstract] [Full Text] [PDF]

				X. Xu, J. Ding, G. Rao, J. Shen, R. A. Prinz, N. Rana, and W.P. Dmowski Estradiol induces heparanase-1 expression and heparan sulphate proteoglycan degradation in human endometrium Hum. Reprod., April 1, 2007; 22(4): 927 - 937. [Abstract] [Full Text] [PDF]

				M. E. Wierman Sex steroid effects at target tissues: mechanisms of action Advan Physiol Educ, March 1, 2007; 31(1): 26 - 33. [Abstract] [Full Text] [PDF]

				S. Kousteni, M. Almeida, L. Han, T. Bellido, R. L. Jilka, and S. C. Manolagas Induction of Osteoblast Differentiation by Selective Activation of Kinase-Mediated Actions of the Estrogen Receptor Mol. Cell. Biol., February 15, 2007; 27(4): 1516 - 1530. [Abstract] [Full Text] [PDF]

				N. Vasudevan and D. W. Pfaff Membrane-Initiated Actions of Estrogens in Neuroendocrinology: Emerging Principles Endocr. Rev., February 1, 2007; 28(1): 1 - 19. [Abstract] [Full Text] [PDF]

				M. Fan, P. S. Yan, C. Hartman-Frey, L. Chen, H. Paik, S. L. Oyer, J. D. Salisbury, A. S.L. Cheng, L. Li, P. H. Abbosh, et al. Diverse Gene Expression and DNA Methylation Profiles Correlate with Differential Adaptation of Breast Cancer Cells to the Antiestrogens Tamoxifen and Fulvestrant Cancer Res., December 15, 2006; 66(24): 11954 - 11966. [Abstract] [Full Text] [PDF]

				U. Ohnemus, M. Uenalan, J. Inzunza, J.-A. Gustafsson, and R. Paus The Hair Follicle as an Estrogen Target and Source Endocr. Rev., October 1, 2006; 27(6): 677 - 706. [Abstract] [Full Text] [PDF]

				A. K. Iyer, Y.-H. Zhang, and E. R. B. McCabe Dosage-Sensitive Sex Reversal Adrenal Hypoplasia Congenita Critical Region on the X Chromosome, Gene 1 (DAX1) (NR0B1) and Small Heterodimer Partner (SHP) (NR0B2) Form Homodimers Individually, as Well as DAX1-SHP Heterodimers Mol. Endocrinol., October 1, 2006; 20(10): 2326 - 2342. [Abstract] [Full Text] [PDF]

				Z. Zhang, K. Chen, J. C. Shih, and C. T. Teng Estrogen-Related Receptors-Stimulated Monoamine Oxidase B Promoter Activity Is Down-Regulated by Estrogen Receptors Mol. Endocrinol., July 1, 2006; 20(7): 1547 - 1561. [Abstract] [Full Text] [PDF]

				H. Gao, G. Bryzgalova, E. Hedman, A. Khan, S. Efendic, J.-A. Gustafsson, and K. Dahlman-Wright Long-Term Administration of Estradiol Decreases Expression of Hepatic Lipogenic Genes and Improves Insulin Sensitivity in ob/ob Mice: A Possible Mechanism Is through Direct Regulation of Signal Transducer and Activator of Transcription 3 Mol. Endocrinol., June 1, 2006; 20(6): 1287 - 1299. [Abstract] [Full Text] [PDF]

				F. A. Champagne, I. C. G. Weaver, J. Diorio, S. Dymov, M. Szyf, and M. J. Meaney Maternal Care Associated with Methylation of the Estrogen Receptor-{alpha}1b Promoter and Estrogen Receptor-{alpha} Expression in the Medial Preoptic Area of Female Offspring Endocrinology, June 1, 2006; 147(6): 2909 - 2915. [Abstract] [Full Text] [PDF]

				A. J. Mhyre, R. A. Shapiro, and D. M. Dorsa Estradiol Reduces Nonclassical Transcription at Cyclic Adenosine 3',5'-Monophosphate Response Elements in Glioma Cells Expressing Estrogen Receptor Alpha Endocrinology, April 1, 2006; 147(4): 1796 - 1804. [Abstract] [Full Text] [PDF]

				A. E. Gururaj, S. K. Rayala, R. K. Vadlamudi, and R. Kumar Novel Mechanisms of Resistance to Endocrine Therapy: Genomic and Nongenomic Considerations Clin. Cancer Res., February 1, 2006; 12(3): 1001s - 1007s. [Abstract] [Full Text] [PDF]

				K. F. Allred, E. J. Smart, and M. E. Wilson Estrogen Receptor-{alpha} Mediates Gender Differences in Atherosclerosis Induced by HIV Protease Inhibitors J. Biol. Chem., January 20, 2006; 281(3): 1419 - 1425. [Abstract] [Full Text] [PDF]

				Z. T. Ruiz-Cortes, S. Kimmins, L. Monaco, K. H. Burns, P. Sassone-Corsi, and B. D. Murphy Estrogen Mediates Phosphorylation of Histone H3 in Ovarian Follicle and Mammary Epithelial Tumor Cells via the Mitotic Kinase, Aurora B Mol. Endocrinol., December 1, 2005; 19(12): 2991 - 3000. [Abstract] [Full Text] [PDF]

				T. M. D'Eon, S. C. Souza, M. Aronovitz, M. S. Obin, S. K. Fried, and A. S. Greenberg Estrogen Regulation of Adiposity and Fuel Partitioning: EVIDENCE OF GENOMIC AND NON-GENOMIC REGULATION OF LIPOGENIC AND OXIDATIVE PATHWAYS J. Biol. Chem., October 28, 2005; 280(43): 35983 - 35991. [Abstract] [Full Text] [PDF]

				F. F. Zheng, R.-C. Wu, C. L. Smith, and B. W. O'Malley Rapid Estrogen-Induced Phosphorylation of the SRC-3 Coactivator Occurs in an Extranuclear Complex Containing Estrogen Receptor Mol. Cell. Biol., September 15, 2005; 25(18): 8273 - 8284. [Abstract] [Full Text] [PDF]

				M. E. Mendelsohn and R. H. Karas Molecular and Cellular Basis of Cardiovascular Gender Differences Science, June 10, 2005; 308(5728): 1583 - 1587. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Björnström, L. Articles by Sjöberg, M. Search for Related Content PubMed PubMed Citation Articles by Björnström, L. Articles by Sjöberg, M.